#DWTX hashtag - Bluesky

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.

2 months ago

#DWTX Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain Dogwood Therapeutics (Nasdaq: DWTX) reported a positive interim analysis from 97 patients in its Phase 2b study of Halneuron for chemotherapy induced neuropathic pain (CINP) on Dec 22, 2025. An independent committee found Halneuron-treated patients separated from placebo on pain improvement over four weeks. The company projects top-line results in Q3 2026 and enrollment trends that provide ~80%–85% statistical power. The interim cohort had an average CINP duration of 5 years, with 67% on stable background pain meds; overall dropout was ~4.4%. The company says safety and tolerability remain encouraging, and positive Phase 2b outcomes could support a Phase 3 registration program.

3 months ago

#DWTX Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Therapeutics (Nasdaq: DWTX) files synthetic Halneuron IP, eyes 2045 exclusivity Dogwood Therapeutics files new IP for fully synthetic Halneuron, targeting exclusivity through 2045 as it advances the drug into Phase 3 with higher-yield, lower-cost manufacturing.

4 months ago

#DWTX Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 Dogwood (Nasdaq:DWTX) announced it has enrolled the first 100 patients in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain as of November 11, 2025. The company says early termination rates remain low among the first 80 completers, suggesting tolerability. A prespecified interim sample-size analysis is on track for Q4 2025 to evaluate whether the planned 200-patient sample remains adequate. The study randomizes patients to Halneuron® or placebo, delivers 8 subcutaneous doses over 14 days, follows patients for 28 days, and is running at ~25 US sites, with final data targeted for mid-2026.

4 months ago

#DWTX Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

www.stocktitan.net/news/DWTX/dogwood-announ...

0 0 0 0

4 months ago

#DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25… buff.ly/zDd83ic

0 0 0 0

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results Dogwood Therapeutics (Nasdaq: DWTX) reported Q3 2025 results and strategic updates on Nov 6, 2025. Key operational items: 100 patients enrolled in the Halneuron® Phase 2b trial with 80 completing treatment, and the prespecified interim analysis remains on track for Q4 2025 with final 200‑patient data expected in H2 2026. The company closed an exclusive worldwide, royalty‑free license to develop SP16 in an all‑stock transaction. Financials: Q3 R&D expense was $14.5M (vs $0.5M prior year) driven by a $12.0M acquired in‑process R&D charge; net loss was $15.7M or $8.20 per share. Cash of $10.1M provides runway through Q1 2026.

4 months ago

#DWTX Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

5 months ago

#DWTX: Licenses SP16 for Treatment of Cancer Related Pain… buff.ly/8QTzxvQ

0 0 0 0

Most Searched, Monday September 29, 2025 – Crystal Equity Research

6 months ago

Most searched small-cap stocks, Mon Sept 29th - #EOSE #KALA #RZLV #RXRX #DWTX #HIVE #RR #BQ #LRMR #RIG #BYND #ONDS #PLUG #BBAI #DNN #TLRY #LUNR #LAC #NEOG - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

7 months ago

#DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25 buff.ly/jHpJkDG

0 0 0 0

Dogwood's Non-Opioid Pain Drug Advances With Strong Safety Data in Phase 2b Cancer Trial Novel pain treatment Halneuron shows promising 94.2% retention rate in cancer pain trial. Biotech reports $13.4M cash runway through Q1 2026. Key data expected Q4 2025. Get insights.

7 months ago

#DWTX Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial Dogwood Therapeutics (NASDAQ:DWTX) has reached a significant milestone in its Phase 2b clinical trial for Halneuron®, enrolling the first 50 patients to evaluate the drug's effectiveness in treating Chemotherapy-Induced Neuropathic Pain (CINP). The trial, known as HALT-CINP, demonstrates promising early safety data with only a 6% discontinuation rate among the first 35 patients.The study focuses on cancer patients with neuropathy from platinum or taxane-based chemotherapy, administering 8 daily subcutaneous doses over 14 days with a 28-day follow-up. The company remains on track for its Q4 2025 interim analysis of approximately 100 patients, with full results expected in mid-2026. The trial will be conducted across 25 U.S. sites, evaluating primary endpoints of safety and pain intensity reduction.

7 months ago

#DWTX Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks in new uptrend in Average Directional Index, Mon Jun 23rd - #INLF #GNLX #DWTX #VVOS #RFIL #PXLM #OLPX #NN #IMDX #CCNE #BASE #TXO #TEN #SQNS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

10 months ago

#DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway… buff.ly/sNsBstJ

1 0 0 0

Dogwood Therapeutics Announces First Quarter 2025 Financial Results Dogwood Therapeutics (DWTX) reported Q1 2025 financial results and key developments. The company has begun dosing patients in its Halneuron® Phase 2b study for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025. The company's financial position includes $17.5M cash on hand, providing runway through Q1 2026, bolstered by a $4.8M stock raise and conversion of a $19.5M loan to equity by CK Life Sciences. Q1 2025 saw increased R&D expenses of $2.4M (up from $0.3M in Q1 2024) and G&A expenses of $2.0M (up from $1.0M). The net loss was $12.2M or $8.45 per share. The company regained Nasdaq compliance and maintains FDA fast track designation for Halneuron® in CINP treatment.

10 months ago

#DWTX Dogwood Therapeutics Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

11 months ago

Small-cap stocks in new uptrend with average directional index, Tue Apr 22nd - #NG #YGMZ #TIVC #SMX #FER #DWTX #ALTS #SPWR #SLS #LAB #FWRG #CVGW #IIIN #FDP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

11 months ago

Most searched small-cap stocks, Mon Apr 21st - #PTEN #FSM #DWTX #CLSK #TGB #WULF #RIG #SHFS #APLD #UPXI #WOLF #SOUN #SMR #SFL #RGTI #QBTS #OKLO #NXE #MLGO #HTZ - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

11 months ago

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings - American Rebel Holdings (NASDAQ:AREB), Thunder Power Holdings (NASDAQ:AIEV)

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings read more

www.benzinga.com/25/04/44899271/nasdaq-tu...

#AIEV #AREB #DWTX #Earnings #Equities #LXEH #Mid #Morning #Market #Update #News

Result Details

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

11 months ago

Most searched small-cap stocks, Tue Apr 15th - #IREN #SOUN #NGD #UAA #AG #RXRX #TGB #DWTX #VRN #VERV #CLSK #WULF #JBLU #RIG #BBAI #TMC #APLD #UPST #UUUU #FSM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest Biotech firm strengthens financial position, maintains Nasdaq listing while advancing Phase 2b pain treatment trial. Full analysis of growth trajectory inside.

11 months ago

#DWTX Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

11 months ago

#DWTX: Interim Data for Phase 2b Trial in 4Q25… buff.ly/EKRrX8m

0 0 0 0

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the

1 year ago

#DWTX Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results Dogwood Therapeutics (NASDAQ: DWTX) has reported its Q4 and full-year 2024 financial results, highlighting significant developments in its pipeline. The company has begun dosing patients in the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025.Financial highlights include a $19.5M debt-to-equity conversion by major shareholder CK Life Sciences, and a $4.8M common stock raise, extending operational runway through Q1 2026. The company reported a Q4 2024 net loss of $8.2M ($6.29 per share) compared to $1.1M in Q4 2023. Full-year 2024 net loss was $12.9M ($12.52 per share).R&D expenses increased to $2.3M in Q4 2024 from $0.3M in Q4 2023, while G&A expenses rose to $5.2M from $0.8M. Cash position stands at $14.8M as of December 31, 2024.

1 year ago

#DWTX Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

1 year ago

#DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… buff.ly/VOpEdsl

0 0 0 0

Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients Dogwood's Halneuron shows promise in $1.5B chemotherapy pain market. Previous trials demonstrated significant pain reduction with no addiction risk across 700+ patients.

1 year ago

#DWTX Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0

Dogwood Secures Critical Funding for Revolutionary Pain Treatment: What's Next for Halneuron? Fresh capital extends Dogwood's runway through 2026, accelerating Halneuron development for chemotherapy pain. Phase 2b trial results expected Q4 2025.

1 year ago

#DWTX Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/DWTX/dogwood-therap...

0 0 0 0